公开(公告)号：WO2019108570A3

公开(公告)日：2019-06-06

申请号：PCT/US2018/062712

申请日：2018-11-28

Applicant: COPERNICUS THERAPEUTICS, INC. ,  CLEARSIDE BIOMEDICAL

Inventor： TARABORELLI, Donna ,  YOO, Jesse ,  NORONHA, Glenn ,  COOPER, Mark J. ,  MOEN, Robert C. ,  WHITE, Daniel

IPC: A61K48/00 ,  A61K9/00 ,  A61K31/7088 ,  A61P27/02

Abstract: Targeted non-surgical administration of a nucleic acid formulation to the suprachoroidal space (SCS) of the eye of a human subject permits effective treatment of ocular disorders, including posterior ocular or choroidal maladies. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a nucleic acid formulation through the inserted microneedle and into the suprachoroidal space of the eye. The infused nucleic acid formulation flows within the suprachoroidal space away from the insertion site. In one embodiment, the fluid nucleic acid formulation comprises nucleic acid nanoparticles consisting of one molecule of nucleic acid.

公开(公告)号：WO2019108570A2

公开(公告)日：2019-06-06

申请号：PCT/US2018/062712

申请日：2018-11-28

Applicant: COPERNICUS THERAPEUTICS, INC. ,  CLEARSIDE BIOMEDICAL

Inventor： TARABORELLI, Donna ,  YOO, Jesse ,  NORONHA, Glenn ,  COOPER, Mark J. ,  MOEN, Robert C. ,  WHITE, Daniel

CPC classification number: A61K48/0075 ,  A61K48/0008

Abstract: Targeted non-surgical administration of a nucleic acid formulation to the suprachoroidal space (SCS) of the eye of a human subject permits effective treatment of ocular disorders, including posterior ocular or choroidal maladies. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a nucleic acid formulation through the inserted microneedle and into the suprachoroidal space of the eye. The infused nucleic acid formulation flows within the suprachoroidal space away from the insertion site. In one embodiment, the fluid nucleic acid formulation comprises nucleic acid nanoparticles consisting of one molecule of nucleic acid.

公开(公告)号：WO2015195842A1

公开(公告)日：2015-12-23

申请号：PCT/US2015/036299

申请日：2015-06-17

Applicant: CLEARSIDE BIOMEDICAL, INC. ,  NORONHA, Glenn

Inventor： NORONHA, Glenn ,  BROOKS, Christopher John ,  ANDINO, Rafael Victor ,  PATEL, Samirkumar ,  WHITE, Daniel

IPC: A61F2/00 ,  A61F9/00 ,  A61M31/00

CPC classification number: A61F9/0008 ,  A61K9/0019 ,  A61K9/0048 ,  A61K31/573 ,  A61K47/38

Abstract: The present invention relates to a methods and devices for treating uveitis, macular edema associated with uveitis and macular edema associated with retinal vein occlusion in a human subject in need thereof. In certain aspects, devices provided herein include a medicament container defining a lumen configured to contain a medicament, a distal end portion of the medicament container including a coupling portion configured to be removably coupled to a needle assembly, a proximal end portion of the medicament container including a flange and a longitudinal shoulder; a piston assembly including a distal end portion movably disposed within the lumen of the medicament container; and a handle coupled to a proximal end portion of the piston assembly.

Abstract translation: 本发明涉及用于治疗葡萄膜炎的黄斑水肿，与需要其的人类受试者相关的葡萄膜炎和与视网膜静脉阻塞相关的黄斑水肿。 在某些方面，本文提供的装置包括限定被配置为容纳药物的内腔的药物容器，药物容器的远端部分包括构造成可拆卸地联接到针组件的联接部分，药物容器的近端部分 包括凸缘和纵向肩部; 活塞组件，包括可移动地设置在药物容器的内腔内的远端部分; 以及联接到所述活塞组件的近端部分的手柄。

公开(公告)号：WO2014074823A1

公开(公告)日：2014-05-15

申请号：PCT/US2013/069156

申请日：2013-11-08

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： ZARNITSYN, Vladimir ,  PATEL, Samirkumar ,  WHITE, Daniel ,  NORONHA, Glenn ,  BURKE, Brian

IPC: A61K9/16 ,  A61P27/02

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

Abstract translation: 提供了用于将药物制剂靶向非手术施用于人受试者眼睛的脉络膜上空间（SCS）以用于治疗后眼部疾病或脉络膜性疾病的方法和装置。 在一个实施例中，该方法包括在插入部位将中空微针插入眼睛，并将药物制剂通过插入的微针并进入眼睛的脉络膜上空间，其中输注的药物制剂在远离插入物的脉管外空间内流动 输液过程中的位置。 在一个实施方案中，流体药物制剂包含药物纳米颗粒或微粒。